Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.

IF 2.7 Q3 IMMUNOLOGY

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-18 DOI:10.1080/25785826.2024.2304364

Ritsu Akatani, Norio Chihara, Shusuke Koto, Sotaro Mori, Takuji Kurimoto, Makoto Nakamura, Hisatsugu Tachibana, Yoshihisa Otsuka, Takehiro Ueda, Takashi Omori, Kenji Sekiguchi, Riki Matsumoto

{"title":"Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.","authors":"Ritsu Akatani, Norio Chihara, Shusuke Koto, Sotaro Mori, Takuji Kurimoto, Makoto Nakamura, Hisatsugu Tachibana, Yoshihisa Otsuka, Takehiro Ueda, Takashi Omori, Kenji Sekiguchi, Riki Matsumoto","doi":"10.1080/25785826.2024.2304364","DOIUrl":null,"url":null,"abstract":"Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease that can affect multiple generations and cause complications with long-term prednisolone treatment. This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) in preventing NMOSD relapse while reducing prednisolone dosage. The trial involved nine patients with NMOSD who received MMF along with prednisolone dose reduction. MMF was effective in achieving prednisolone dose reduction without relapse in 77.8% of patients, with a significant decrease in mean annualized relapse rate. All adverse events were mild. The findings suggest that MMF could be a viable treatment option for middle-aged and older patients who require steroid reduction.Clinical trial registration number: jRCT, jRCTs051180080. Registered February 27th, 2019-retrospectively registered, https://jrct.niph.go.jp/en-latest-detail/jRCTs051180080.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"85-92"},"PeriodicalIF":2.7000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/25785826.2024.2304364","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease that can affect multiple generations and cause complications with long-term prednisolone treatment. This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) in preventing NMOSD relapse while reducing prednisolone dosage. The trial involved nine patients with NMOSD who received MMF along with prednisolone dose reduction. MMF was effective in achieving prednisolone dose reduction without relapse in 77.8% of patients, with a significant decrease in mean annualized relapse rate. All adverse events were mild. The findings suggest that MMF could be a viable treatment option for middle-aged and older patients who require steroid reduction.Clinical trial registration number: jRCT, jRCTs051180080. Registered February 27th, 2019-retrospectively registered, https://jrct.niph.go.jp/en-latest-detail/jRCTs051180080.

查看原文本刊更多论文

前瞻性队列研究：霉酚酸酯减少神经脊髓炎视网膜频谱障碍类固醇用药的有效性和安全性。

神经脊髓炎视谱系障碍（NMOSD）是一种罕见的自身免疫性炎症疾病，可影响多代人，长期泼尼松龙治疗可引起并发症。这项研究旨在评估霉酚酸酯（MMF）在减少泼尼松龙用量的同时预防NMOSD复发的有效性和安全性。试验涉及九名 NMOSD 患者，他们在接受 MMF 治疗的同时减少了泼尼松龙的剂量。在77.8%的患者中，MMF能有效减少泼尼松龙剂量而不复发，平均年复发率显著降低。所有不良反应均较轻微。研究结果表明，对于需要减少类固醇用量的中老年患者来说，MMF可能是一种可行的治疗选择。临床试验注册号：jRCT，jRCTs051180080。注册时间：2019年2月27日-回顾注册，https://jrct.niph.go.jp/en-latest-detail/jRCTs051180080。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊